NRC 📈 National Research - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6373722023
NRC: Analytics, Insights, Patient Experience, Employee Engagement, Reputation Management
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, employee engagement, reputation management, and brand loyalty. The company also offers marketing solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient experience, employee engagement, health risk assessments, care transition, and improvement tools. Further, the company provides reputation solutions that allow healthcare organizations to share a picture of their organization and ensure that timely and relevant content informs consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska. Web URL: https://www.nrchealth.com
Additional Sources for NRC Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NRC Stock Overview
Market Cap in USD | 462m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1997-10-10 |
NRC Stock Ratings
Growth 5y | -91.5% |
Fundamental | 57.2% |
Dividend | 46.2% |
Rel. Strength Industry | -1185 |
Analysts | 4/5 |
Fair Price Momentum | 12.50 USD |
Fair Price DCF | 27.75 USD |
NRC Dividends
Dividend Yield 12m | 3.49% |
Yield on Cost 5y | 0.97% |
Annual Growth 5y | 13.67% |
Payout Consistency | 76.8% |
NRC Growth Ratios
Growth Correlation 3m | -45.7% |
Growth Correlation 12m | -95.4% |
Growth Correlation 5y | -73.9% |
CAGR 5y | -22.50% |
CAGR/Mean DD 5y | -0.59 |
Sharpe Ratio 12m | -1.92 |
Alpha | -80.43 |
Beta | 0.92 |
Volatility | 39.59% |
Current Volume | 333.5k |
Average Volume 20d | 114.1k |
What is the price of NRC stocks?
As of December 22, 2024, the stock is trading at USD 17.17 with a total of 333,536 shares traded.
Over the past week, the price has changed by -3.49%, over one month by -8.43%, over three months by -20.23% and over the past year by -55.83%.
As of December 22, 2024, the stock is trading at USD 17.17 with a total of 333,536 shares traded.
Over the past week, the price has changed by -3.49%, over one month by -8.43%, over three months by -20.23% and over the past year by -55.83%.
Is National Research a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, National Research (NASDAQ:NRC) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.15 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NRC as of December 2024 is 12.50. This means that NRC is currently overvalued and has a potential downside of -27.2%.
Partly, yes. Based on ValueRay Fundamental Analyses, National Research (NASDAQ:NRC) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 57.15 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NRC as of December 2024 is 12.50. This means that NRC is currently overvalued and has a potential downside of -27.2%.
Is NRC a buy, sell or hold?
National Research has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NRC.
National Research has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NRC.
- Strong Buy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for NRC stock price target?
According to ValueRays Forecast Model, NRC National Research will be worth about 13.8 in December 2025. The stock is currently trading at 17.17. This means that the stock has a potential downside of -19.63%.
According to ValueRays Forecast Model, NRC National Research will be worth about 13.8 in December 2025. The stock is currently trading at 17.17. This means that the stock has a potential downside of -19.63%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 13.8 | -19.6% |